Find Clinical Trial
A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with bisphosphonates
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Rheumatology |
| Indication | Osteoporosis |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
STRONTIUM RANELATE, |
| Active Substance Code | S012911 |
| Protocol Code | CL3-12911-038 |
| EudraCT Code | 2011-000708-17 |
Documents and links
| Results summary | READ MORE  |
Quote
| "A 24months, prospective, randomised, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate vs.placebo on BMD in postmenopausal osteoporotic women previously treated with bisphosphonates. D. Felsenberg, R. Chapurlat, R. Rizzoli, J.-Y. Reginster, P. Belissa- Mathiot. Osteoporosis International, Volume 29, Supplement 1, April 2018 Presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2018, April 19-22, 2018, Krakow, Poland Abstract No. P426" |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
